Current and future landscape of PARPi resistance

od Hinchcliff, Emily, Chelariu-Raicu, Anca, Westin, Shannon N.
Izdano u Curr Opin Obstet Gynecol (2021)

Targeting KRAS in Cancer: Promising Therapeutic Strategies

od Mustachio, Lisa Maria, Chelariu-Raicu, Anca, Szekvolgyi, Lorant, Roszik, Jason
Izdano u Cancers (Basel) (2021)

Expression of the Carbohydrate Lewis Antigen, Sialyl Lewis A, Sialyl Lewis X, Lewis X, and Lewis Y in the Placental Villi of Patients With Unexplained Miscarriages

od Ma, Zhi, Yang, Huixia, Peng, Lin, Kuhn, Christina, Chelariu-Raicu, Anca, Mahner, Sven, Jeschke, Udo, von Schönfeldt, Viktoria
Izdano u Front Immunol (2021)

Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile

od Zheng, Mingjun, Mullikin, Heather, Hester, Anna, Czogalla, Bastian, Heidegger, Helene, Vilsmaier, Theresa, Vattai, Aurelia, Chelariu-Raicu, Anca, Jeschke, Udo, Trillsch, Fabian, Mahner, Sven, Kaltofen, Till
Izdano u Int J Mol Sci (2020)

Blockade of the short Form of prolactin receptor induces FOXO3a/EIF-4EBP1–mediated cell death in uterine cancer

od Wen, Yunfei, Wang, Ying, Chelariu-Raicu, Anca, Stur, Elaine, Liu, Yuan, Corvigno, Sara, Bartsch, Faith, Redfern, Lauren, Zand, Behrouz, Kang, Yu, Liu, Jinsong, Baggerly, Keith, Sood, Anil K.
Izdano u Mol Cancer Ther (2020)

Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer

od Zheng, Mingjun, Long, Junyu, Chelariu-Raicu, Anca, Mullikin, Heather, Vilsmaier, Theresa, Vattai, Aurelia, Heidegger, Helene Hildegard, Batz, Falk, Keckstein, Simon, Jeschke, Udo, Trillsch, Fabian, Mahner, Sven, Kaltofen, Till
Izdano u Cancers (Basel) (2021)

Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions

od Xiong, Chiyi, Wen, Yunfei, Zhao, Jun, Yin, Dengke, Xu, Lingyun, Chelariu-Raicu, Anca, Yao, Cody, Leng, Xiaohong, Liu, Jinsong, Chaudhari, Rajan R., Zhang, Shuxing, Sood, Anil K., Li, Chun
Izdano u Sci Rep (2020)